Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura:: a randomised, multicentre trial

被引:194
作者
Godeau, B
Chevret, S
Varet, B
Lefrère, F
Zini, JM
Bassompierre, F
Chèze, S
Legouffe, E
Hulin, C
Grange, MJ
Fain, O
Bierling, P
机构
[1] Hop Henri Mondor, Assistance Publ Hop Paris,EFS Ile France, Lab Immunol Leucoplaquettaire, Serv Med Interne, F-94000 Creteil, France
[2] Hop St Louis, Assistance Publ Hop Paris, Dept Biostat & Informat Med, Paris, France
[3] Hop Necker Enfants Malad, Assistance Publ Hop Paris, Hematol Serv, Paris, France
[4] Hop Lariboisiere, Assistance Publ Hop Paris, Hematol Serv, F-75475 Paris, France
[5] Hop St Louis, Assistance Publ Hop Paris, DRC, Paris, France
[6] Hop Cote de Necre, Hematol Serv, Caen, France
[7] Hop Lareyronie, Hematol Serv, Montpellier, France
[8] Hop Brabois, Hematol Serv, Nancy, France
[9] Hop Bichat Claude Bernard, Dept Hematol Biol, Assistance Publ Hop Paris, F-75877 Paris, France
[10] Hop Jean Verdier, Assistance Publ Hop Paris, Serv Med Interne, Bondy, France
关键词
D O I
10.1016/S0140-6736(02)07275-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Treatment of adults with autoimmune thrombocytopenic purpura (AITP) is based more on individual experience than on results of controlled studies, We compared intravenous immunoglobulin with high-dose methylprednisolone in untreated adults with severe AITP and assessed efficacy of subsequent oral steroids compared with placebo. Primary outcome was number of days with platelet count greater than 50x10(9)/L within the first 21 days. Methods We did a randomised multicentre trial based on a 2x2 design. 122 adults with severe AITP (platelet count less than or equal to 20x10(9)/L) were randomly assigned to receive either intravenous immunoglobulin or high-dose methylprednisolone on days 1-3 (randomisation A), and then to receive either oral prednisone or placebo (randomisation B) on days 4-21. Analysis was by intention to treat. Findings Six patients were excluded from the analysis. The number of days ori-which platelet counts were above 50x10(9)/L was 18 in 56 patients receiving intravenous immunoglobulin and 14 in 60 receiving high-dose methylprednisolone (p=0.02). Percentage of patients who had platelet counts over 50x10(9)/L on days 2 and 5 was 7% and 79%, respectively, in the intravenous immunoglobulin group compared with 2% and 60%, respectively, in the high-dose methylprednisolone group (p=0.04). During the second treatment period, prednisone was more effective than placebo for all short-term endpoints. Patients who received intravenous immunoglobulin and prednisone had platelet count greater than 50x10(9)/L for 18.5 days (p=0.005), and those treated with high-dose methylprednisolone and prednisone had this count for 17.5 days. Interpretation Intravenous immunoglobulin and oral prednisone seems to be more effective than high-dose methylprednisolone and oral prednisone in adults with severe AITP, although the latter treatment is effective and well tolerated.
引用
收藏
页码:23 / 29
页数:7
相关论文
共 25 条
[1]   ACUTE IMMUNE THROMBOCYTOPENIC PURPURA - A COMPARATIVE-STUDY OF VERY HIGH ORAL DOSES OF METHYLPREDNISOLONE AND INTRAVENOUSLY ADMINISTERED IMMUNE GLOBULIN [J].
ALBAYRAK, D ;
ISLEK, I ;
KALAYCI, AG ;
GURSES, N .
JOURNAL OF PEDIATRICS, 1994, 125 (06) :1004-1007
[2]   Efficacy of high-dose methylprednisolone as a first-line therapy in adult patients with idiopathic thrombocytopenic purpura [J].
Alpdogan, Ö ;
Budak-Alpdogan, T ;
Ratip, S ;
Firatli-Tuglular, T ;
Tanriverdi, S ;
Karti, S ;
Bayik, M ;
Akoglu, T .
BRITISH JOURNAL OF HAEMATOLOGY, 1998, 103 (04) :1061-1063
[3]  
Altintop L, 1997, AM J HEMATOL, V56, P191, DOI 10.1002/(SICI)1096-8652(199711)56:3<191::AID-AJH12>3.0.CO
[4]  
2-E
[5]  
BARRIOS NJ, 1993, ACTA HAEMATOL-BASEL, V89, P6
[6]   A PROSPECTIVE, RANDOMIZED TRIAL OF HIGH-DOSE INTRAVENOUS IMMUNE GLOBULIN G THERAPY, ORAL PREDNISONE THERAPY, AND NO THERAPY IN CHILDHOOD ACUTE IMMUNE THROMBOCYTOPENIC PURPURA [J].
BLANCHETTE, VS ;
LUKE, B ;
ANDREW, M ;
SOMMERVILLENIELSEN, S ;
BARNARD, D ;
DEVEBER, B ;
GENT, M .
JOURNAL OF PEDIATRICS, 1993, 123 (06) :989-995
[7]   INTRAVENOUS TREATMENT WITH GAMMA-GLOBULIN IN ADULTS WITH IMMUNE THROMBOCYTOPENIC PURPURA - REVIEW OF THE LITERATURE [J].
BUSSEL, JB ;
PHAM, LC .
VOX SANGUINIS, 1987, 52 (03) :206-211
[8]   The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts [J].
Cohen, YC ;
Djulbegovic, B ;
Shamai-Lubovitz, O ;
Mozes, B .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (11) :1630-1638
[9]   The incidence of idiopathic thrombocytopenic purpura in adults increases with age [J].
Frederiksen, H ;
Schmidt, K .
BLOOD, 1999, 94 (03) :909-913
[10]   Idiopathic thrombocytopenic purpura: Lessons from a guideline [J].
George, JN ;
Davidoff, F .
ANNALS OF INTERNAL MEDICINE, 1997, 126 (04) :317-318